2) “Whether these patients were at high risk of rebound or reinfection should be explored in further studies,” the team wrote. #COVID19

— Eric Feigl-Ding (@DrEricDing) April 8, 2020

3) Antibodies are generated by the immune system and have unique chemical structures to inhibit specific pathogens. The coronavirus antibody intercepts the spike protein on the viral envelope to prevent it from binding with human cells. #COVID19

— Eric Feigl-Ding (@DrEricDing) April 8, 2020

4) “researchers said they were surprised to find that the antibody “titer” value in about a third of the patients was less than 500, a level that might be too low to provide protection.” #COVID19

— Eric Feigl-Ding (@DrEricDing) April 8, 2020

5) “About 30 per cent of patients failed to develop high titers of neutralising antibodies after #Covid19 infection. However, the disease duration of these patients compared to others was similar," they said.

— Eric Feigl-Ding (@DrEricDing) April 8, 2020

6) “The team also found that antibody levels rose with age, with people in the 60-85 age group displaying more than three times the amount of antibodies as people in the 15-39 age group.” #COVID19

— Eric Feigl-Ding (@DrEricDing) April 8, 2020

7) low amounts of antibodies could affect herd immunity, resistance to the disease among the general population to stop its spread. “What this will mean to herd immunity will require more data from other parts of the world,” Professor Huang Jinghe, leader of team, said. #COVID19

— Eric Feigl-Ding (@DrEricDing) April 8, 2020

8) “Vaccine developers may need to pay particular attention to these patients,” Huang said. If the real virus could not induce antibody response, the weakened version in the vaccine might not work in these patients either. #COVID19

— Eric Feigl-Ding (@DrEricDing) April 8, 2020

9) The researchers also found that #Covid19 antibody could bind with a distantly related strain SARS-1 in 2003. But the binding could not suppress SARS-1 virus replication in cells, dashing hopes of developing a vaccine for two or even more coronavirus strains at once.

— Eric Feigl-Ding (@DrEricDing) April 8, 2020

10) “Who knows whether #COVID19 will become something like seasonal flu, or chronic disease like hepatitis B, or just vanish like Sars?” he said. “Up till now we still lack imagination [to tell].” Translation: now it’s looks worse than before.

— Eric Feigl-Ding (@DrEricDing) April 8, 2020

No, not concerning. Only the covid-19 surface spiked protein was tested, which is unreliable. The more reliable nucleocapsid protein wasn’t. And u didn’t link the original submission, just a reporter’s interpretation. Here u go, but it’s only an abstract.https://t.co/pErcHibx7J

— Rajiv Pandit (@rajiv_pandit) April 8, 2020

⚠️PLASMA TRANSFUSION: Whoa - plasma from recovered #COVID19 patients tested in 10 severe cases showed that 1 dose (200 mL) of CP could increase or maintain the neutralizing antibodies at a high level, symptoms improved in 3 days, w/ viral load gone in 7 d. https://t.co/y0fUTmJbGs

— Eric Feigl-Ding (@DrEricDing) April 9, 2020